Top of page
Global Site Navigation

School of Science

Local Section Navigation
You are here: Main Content

Dr Joel P.A. Gummer

Post Doctoral Research Fellow

Staff Member Details
Campus: Joondalup  
Room: JO19.364  

Joel is a Post Doctoral Research Fellow, jointly appointed between ECU’s School of Science and the ChemCentre.


Joel specialises in the use of mass spectrometry-based platforms for characterising the metabolomes and proteomes of biological systems. Joel is jointly appointed with the ChemCentre, Western Australia’s premier chemical science facility, within the Forensic Proteomics team, and holds honourary appointments with the School of Surgery at the University of Western Australia and Curtin University. Joel was the former National Head of Analytics for Metabolomics Australia, based as Murdoch University, and Affiliate Academic with the Lee Kong Chian School of Medicine at the Nanyang Technological University (NTU) of Singapore. More recently, Joel helped establish the Australian National Phenome Centre and held a position of Analytical Specialist.

Professional Memberships

  • 2020 - Australasian Proteomics Society, APS (Member)
  • 2019 - Accelerating Australia (MTPConnect), WA (Sub-Committee Member)
  • 2018-19 – Metabolomics Australia (National Head of Analytics)
  • 2015-18 – International Metabolomics Society (Member)
  • 2015-18 – American Society for Mass Spectrometry, ASMS (Member)
  • 2010 - Australian and New Zealand Society for Mass Spectrometry, ANZSMS (Member)

Research Areas and Interests

  • Proteomics
  • Peptidomics
  • Metabolomics
  • Mass Spectrometry
  • Chromatography
  • Iron Metabolism
  • Systems Biology
  • Disease mechanisms
  • Conservation Biology
  • Commercialisation


  • Doctor of Philosophy, Murdoch University, 2012.

Recent Publications (within the last five years)

Journal Articles

  • Abbiss, H., Gummer, J., Francki, M., Trengove, RD., (2020), Untargeted liquid chromatography-mass spectrometry-based metabolomics analysis of wheat grain. Journal of Visualized Experiments, March(157), e60851, United States, DOI: 10.3791/60851.
  • Mead, MK., Claus, M., Litton, E., Smart, L., Raisis, A., Rossi, G., Trengrove, RD., Gummer, J., (2019), Identification of the Canidae iron regulatory hormone hepcidin. Scientific Reports, 9(1), Article number 19400, DOI: 10.1038/s41598-019-55009-w.
  • Abbiss, H., Maker, GL., Gummer, J., Rawlinson, C., Musk, GC., Fleming, PA., Phillips, JK., Boyce, M., Trengove, RD., (2019), Untargeted gas chromatography–mass spectrometry-based metabolomics analysis of kidney and liver tissue from the Lewis Polycystic Kidney rat. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1118-1119(15 June 2019), 25-32, DOI: 10.1016/j.jchromb.2019.04.021.
  • Lawler, N., Abbiss, C., Gummer, J., Broadhurst, D., Govus, A., Fairchild, T., Thompson, K., Garvican-Lewis, L., Gore, C., Maker, G., Trengove, R., Peiffer, J., (2019), Characterizing the plasma metabolome during 14 days of live-high, train-low simulated altitude: A metabolomic approach. Experimental Physiology, 104(1), 81-92, United Kingdom, Wiley-Blackwell Publishing Ltd., DOI: 10.1113/EP087159.
  • Britton, L., Bridle, K., Reiling, J., Santrampurwala, N., Wockner, L., Ching, H., Stuart, K., Subramaniam, VN., Jeffrey, G., St Pierre, T., House, M., Gummer, J., Trengove, R., Olynyk, J., Crawford, D., Adams, L., (2018), Hepatic iron concentration correlates with insulin sensitivity in non-alcoholic fatty liver disease. Hepatology Communications, 2(6), 644-653, DOI: 10.1002/hep4.1190.
  • Litton, E., Baker, S., Erber, W., Farmer, S., Ferrier, J., French, C., Gummer, J., Hawkins, D., Higgins, A., Hofmann, A., De Keulenaer, B., McMorrow, J., Olynyk, J., Richards, T., Towler, S., Trengove, R., Webb, S., (2018), Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study. Journal of Intensive Care, 6(1), Article no.60, DOI: 10.1186/s40560-018-0328-2.
  • Gummer, J., Trengove, R., Pascoe, EM., Badve, SV., Cass, A., Clarke, P., McDonald, SP., Morrish, AT., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, LA., Hawley, CM., Johnson, DW., Olynyk, J., Ferrari, P., (2017), Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology, 22(7), 548-554, Australia, Wiley-Blackwell Publishing Asia, DOI: 10.1111/nep.12815.
  • Ironman Investigators, T., Litton, E., Baker, S., Erber, W., Farmer, S., Ferrier, J., French, C., Gummer, J., Hawkins, D., Higgins, A., Hofmann, A., De Keulenaer, B., McMorrow, J., Olynyk, J., Richards, T., Towler, S., Trengove, R., Webb, S., Anzics Clinical Trials Group, T., (2016), Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: A randomized trial of IV iron in critical illness. Intensive Care Medicine, 42(11), 1715-1722, DOI: 10.1007/s00134-016-4465-6.
  • Van Rijnsoever, M., Galhenage, S., Mollison, L., Gummer, J., Trengove, R., Olynyk, J., (2016), Dysregulated erythropoietin, hepcidin, and bone marrow iron metabolism contribute to interferon-induced anemia in hepatitis C. Journal of Interferon and Cytokine Research, 36(11), 630-634, Mary Ann Liebert, DOI: 10.1089/jir.2016.0043.
Skip to top of page